BRPI0915887A2 - derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c - Google Patents

derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c

Info

Publication number: BRPI0915887A2
Authority: BR; Brazil
Prior art keywords: hepatitis; indole derivatives; derivatives useful; virus inhibitors; macrocyclic indole
Prior art date: 2008-07-08

Application number

BRPI0915887A

Other languages

English (en)

Inventor

Abdellah Tahri

Katie Ingrid Eduard Amssoms

Pierre Jean-Marie Bernard Raboisson

Sandrine Marie Hélène Vendeville

Tse-I Lin

Original Assignee

Tibotec Pharm Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-08

Filing date

2009-07-08

Publication date

2015-11-03

2009-07-08 Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd

2015-11-03 Publication of BRPI0915887A2 publication Critical patent/BRPI0915887A2/pt

2020-02-18 Publication of BRPI0915887B1 publication Critical patent/BRPI0915887B1/pt

2021-05-25 Publication of BRPI0915887B8 publication Critical patent/BRPI0915887B8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI0915887A 2008-07-08 2009-07-08 derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c BRPI0915887B8 (pt)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
EP08159965.6		2008-07-08
EP08159965		2008-07-08
EP08160254		2008-07-11
EP08160254.2		2008-07-11
EP08161743		2008-08-04
EP08161743.3		2008-08-04
PCT/EP2009/004942 WO2010003658A1 (en)	2008-07-08	2009-07-08	Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Publications (3)

Publication Number	Publication Date
BRPI0915887A2 true BRPI0915887A2 (pt)	2015-11-03
BRPI0915887B1 BRPI0915887B1 (pt)	2020-02-18
BRPI0915887B8 BRPI0915887B8 (pt)	2021-05-25

Family

ID=40972916

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0915887A BRPI0915887B8 (pt)	2008-07-08	2009-07-08	derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c

Country Status (31)

Country	Link
US (2)	US8921355B2 (pt)
EP (1)	EP2310396B1 (pt)
JP (2)	JP5426671B2 (pt)
KR (1)	KR101640374B1 (pt)
CN (1)	CN102089314B (pt)
AP (1)	AP2743A (pt)
AR (1)	AR072726A1 (pt)
AU (1)	AU2009267389B8 (pt)
BR (1)	BRPI0915887B8 (pt)
CA (1)	CA2729307C (pt)
CL (1)	CL2011000032A1 (pt)
CO (1)	CO6351793A2 (pt)
CR (1)	CR20110076A (pt)
DK (1)	DK2310396T3 (pt)
EA (1)	EA019008B1 (pt)
EC (1)	ECSP11010750A (pt)
ES (1)	ES2651038T3 (pt)
HN (1)	HN2011000072A (pt)
HR (1)	HRP20171892T1 (pt)
HU (1)	HUE035244T2 (pt)
IL (1)	IL210086A (pt)
LT (1)	LT2310396T (pt)
MX (1)	MX2011000276A (pt)
NI (1)	NI201100010A (pt)
NO (1)	NO2310396T3 (pt)
NZ (2)	NZ590073A (pt)
SI (1)	SI2310396T1 (pt)
SV (1)	SV2011003796A (pt)
TW (1)	TWI454476B (pt)
UY (1)	UY31973A (pt)
WO (1)	WO2010003658A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2238142T3 (da)	2007-12-24	2012-10-08	Janssen R & D Ireland	Makrocykliske indoler som hepatitis C-virusinhibitorer
TWI454476B (zh) *	2008-07-08	2014-10-01	Tibotec Pharm Ltd	用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UA108211C2 (uk) *	2009-11-04	2015-04-10	Янссен Рід Айрленд	Бензімідазолімідазольні похідні
WO2011128378A1 (en)	2010-04-13	2011-10-20	Janssen Pharmaceuticals, Inc.	Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
EP2585438B1 (en) *	2010-06-24	2014-08-20	Janssen R&D Ireland	PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
CN103842330B (zh)	2011-09-02	2016-10-19	诺华股份有限公司	抗炎的取代的环丁烯二酮化合物的胆碱盐
US8716275B2 (en) *	2011-10-20	2014-05-06	Bristol-Myers Squibb Company	Compound for the treatment of hepatitis C
BR112015003913A2 (pt)	2012-08-31	2017-07-04	Janssen Pharmaceuticals Inc	combinação de inibidor macrocíclico da protease do hcv, inibidor do hcv não nucleosídeo e ritonavir
WO2014152275A1 (en) *	2013-03-14	2014-09-25	Concert Pharmaceuticals, Inc.	Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en)	2017-02-10	2019-10-22	Southern Research Institute	Benzo annulenes as antiviral agents
KR101974388B1 (ko)	2017-06-23	2019-05-02	(주)에니켐텍	알킬 디에틸렌 트리아민 유도체 및 이의 제조방법
US11066357B2 (en)	2017-12-26	2021-07-20	Southern Research Institute	Benzoannulene derivatives as antiviral agents
US12274700B1 (en)	2020-10-30	2025-04-15	Accencio LLC	Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US12060148B2 (en)	2022-08-16	2024-08-13	Honeywell International Inc.	Ground resonance detection and warning system and method
CN116425782A (zh) *	2023-03-22	2023-07-14	烟台盛凯伦化学科技有限公司	一种5-乙酰基-2-氟苯硼酸频哪醇酯的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6037157A (en)	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics
US5807876A (en) *	1996-04-23	1998-09-15	Vertex Pharmaceuticals Incorporated	Inhibitors of IMPDH enzyme
US6054472A (en) *	1996-04-23	2000-04-25	Vertex Pharmaceuticals, Incorporated	Inhibitors of IMPDH enzyme
US20050267836A1 (en) *	1996-03-25	2005-12-01	Cfph, Llc	Method and system for transacting with a trading application
PL192628B1 (pl)	1996-04-23	2006-11-30	Vertex Pharma	Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
EP0966465B1 (en)	1997-03-14	2003-07-09	Vertex Pharmaceuticals Incorporated	Inhibitors of impdh enzyme
ES2405316T3 (es)	1999-03-19	2013-05-30	Vertex Pharmaceuticals Incorporated	Inhibidores de la enzima IMPDH
KR100891240B1 (ko)	2000-08-30	2009-04-01	파나소닉 주식회사	플라즈마 디스플레이 표시장치 및 그 제조방법
CA2552319C (en)	2004-01-30	2012-08-21	Medivir Ab	Hcv ns-3 serine protease inhibitors
US7153848B2 (en) *	2004-08-09	2006-12-26	Bristol-Myers Squibb Company	Inhibitors of HCV replication
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
TW200800225A (en)	2005-09-02	2008-01-01	Tibotec Pharm Ltd	Benzodiazepines as HCV inhibitors
US7399758B2 (en) *	2005-09-12	2008-07-15	Meanwell Nicholas A	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en)	2005-11-10	2005-12-21	Angeletti P Ist Richerche Bio	Therapeutic compounds
WO2007092000A1 (en)	2006-02-06	2007-08-16	Bristol-Myers Squibb Company	Inhibitors of hcv replication
US7456166B2 (en) *	2006-05-17	2008-11-25	Bristol-Myers Squibb Company	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) *	2006-05-17	2009-04-21	Bristol-Myers Squibb Company	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) *	2006-05-22	2009-04-21	Bristol-Myers Squibb Company	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) *	2006-05-25	2009-04-21	Bristol-Myers Squibb Company	Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ATE493428T1 (de)	2006-10-10	2011-01-15	Medivir Ab	Hcv-nukleosidinhibitor
CN103224506A (zh) *	2006-12-20	2013-07-31	P.安杰莱蒂分子生物学研究所	抗病毒的吲哚
JP2010533698A (ja) *	2007-07-17	2010-10-28	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー	Ｃ型肝炎感染症の治療のための大環状インドール誘導体
TWI454476B (zh) *	2008-07-08	2014-10-01	Tibotec Pharm Ltd	用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
TW201023858A (en)	2008-09-18	2010-07-01	Ortho Mcneil Janssen Pharm	Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
KR101713066B1 (ko)	2009-02-27	2017-03-07	얀센 파마슈티칼스 인코포레이티드	Ｈｃｖ 마크로사이클릭 저해제의 무정형 염
WO2011128378A1 (en)	2010-04-13	2011-10-20	Janssen Pharmaceuticals, Inc.	Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
EP2585438B1 (en)	2010-06-24	2014-08-20	Janssen R&D Ireland	PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
BR112015003913A2 (pt)	2012-08-31	2017-07-04	Janssen Pharmaceuticals Inc	combinação de inibidor macrocíclico da protease do hcv, inibidor do hcv não nucleosídeo e ritonavir

2009
- 2009-07-07 TW TW098122947A patent/TWI454476B/zh not_active IP Right Cessation
- 2009-07-08 CN CN200980127068.3A patent/CN102089314B/zh active Active
- 2009-07-08 LT LTEP09793887.2T patent/LT2310396T/lt unknown
- 2009-07-08 ES ES09793887.2T patent/ES2651038T3/es active Active
- 2009-07-08 NZ NZ590073A patent/NZ590073A/xx not_active IP Right Cessation
- 2009-07-08 KR KR1020117002865A patent/KR101640374B1/ko not_active Expired - Fee Related
- 2009-07-08 NO NO09793887A patent/NO2310396T3/no unknown
- 2009-07-08 UY UY0001031973A patent/UY31973A/es unknown
- 2009-07-08 BR BRPI0915887A patent/BRPI0915887B8/pt active IP Right Grant
- 2009-07-08 AR ARP090102596A patent/AR072726A1/es unknown
- 2009-07-08 DK DK09793887.2T patent/DK2310396T3/en active
- 2009-07-08 EA EA201170153A patent/EA019008B1/ru not_active IP Right Cessation
- 2009-07-08 MX MX2011000276A patent/MX2011000276A/es active IP Right Grant
- 2009-07-08 US US13/000,583 patent/US8921355B2/en active Active
- 2009-07-08 AU AU2009267389A patent/AU2009267389B8/en not_active Ceased
- 2009-07-08 CA CA2729307A patent/CA2729307C/en active Active
- 2009-07-08 SI SI200931765T patent/SI2310396T1/en unknown
- 2009-07-08 JP JP2011517026A patent/JP5426671B2/ja not_active Expired - Fee Related
- 2009-07-08 WO PCT/EP2009/004942 patent/WO2010003658A1/en not_active Ceased
- 2009-07-08 NZ NZ603343A patent/NZ603343A/xx not_active IP Right Cessation
- 2009-07-08 AP AP2010005521A patent/AP2743A/xx active
- 2009-07-08 HU HUE09793887A patent/HUE035244T2/hu unknown
- 2009-07-08 HR HRP20171892TT patent/HRP20171892T1/hr unknown
- 2009-07-08 EP EP09793887.2A patent/EP2310396B1/en active Active
2010
- 2010-12-19 IL IL210086A patent/IL210086A/en not_active IP Right Cessation
- 2010-12-21 CO CO10160463A patent/CO6351793A2/es active IP Right Grant
2011
- 2011-01-06 NI NI2011000101A patent/NI201100010A/es unknown
- 2011-01-07 HN HN2011000072A patent/HN2011000072A/es unknown
- 2011-01-07 SV SV2011003796A patent/SV2011003796A/es unknown
- 2011-01-07 CL CL2011000032A patent/CL2011000032A1/es unknown
- 2011-01-07 EC EC2011010750A patent/ECSP11010750A/es unknown
- 2011-02-08 CR CR20110076A patent/CR20110076A/es unknown
2013
- 2013-03-15 US US13/836,168 patent/US9427440B2/en active Active
- 2013-08-28 JP JP2013176771A patent/JP5808370B2/ja active Active

Also Published As

Publication number	Publication date
AU2009267389A8 (en)	2013-07-04
EA201170153A1 (ru)	2011-08-30
JP2014028818A (ja)	2014-02-13
UY31973A (es)	2010-01-29
MX2011000276A (es)	2011-03-02
EP2310396A1 (en)	2011-04-20
CO6351793A2 (es)	2011-12-20
HN2011000072A (es)	2013-09-01
ECSP11010750A (es)	2011-08-31
AP2010005521A0 (en)	2010-12-31
EP2310396B1 (en)	2017-09-06
JP2011527299A (ja)	2011-10-27
HUE035244T2 (hu)	2018-05-02
IL210086A (en)	2014-05-28
SI2310396T1 (en)	2018-01-31
US20140107101A1 (en)	2014-04-17
US8921355B2 (en)	2014-12-30
BRPI0915887B8 (pt)	2021-05-25
CR20110076A (es)	2011-11-10
ES2651038T3 (es)	2018-01-23
US9427440B2 (en)	2016-08-30
SV2011003796A (es)	2011-04-08
CA2729307A1 (en)	2010-01-14
KR20110040889A (ko)	2011-04-20
AR072726A1 (es)	2010-09-15
HRP20171892T1 (hr)	2018-01-12
JP5808370B2 (ja)	2015-11-10
BRPI0915887B1 (pt)	2020-02-18
CA2729307C (en)	2017-08-29
NZ603343A (en)	2013-08-30
CN102089314A (zh)	2011-06-08
NO2310396T3 (pt)	2018-02-03
CN102089314B (zh)	2014-07-23
EA019008B1 (ru)	2013-12-30
AU2009267389A1 (en)	2010-01-14
DK2310396T3 (en)	2017-12-11
JP5426671B2 (ja)	2014-02-26
HK1155734A1 (en)	2012-05-25
NZ590073A (en)	2012-11-30
KR101640374B1 (ko)	2016-07-18
LT2310396T (lt)	2017-12-27
WO2010003658A1 (en)	2010-01-14
US20110105473A1 (en)	2011-05-05
CL2011000032A1 (es)	2011-07-15
AP2743A (en)	2013-09-30
IL210086A0 (en)	2011-02-28
TWI454476B (zh)	2014-10-01
TW201014865A (en)	2010-04-16
NI201100010A (es)	2011-09-07
AU2009267389B2 (en)	2013-05-30
AU2009267389B8 (en)	2013-07-04

Publication	Publication Date	Title
BRPI0915887A2 (pt)	2015-11-03	derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c
BRPI0821836A2 (pt)	2015-06-16	Indóis macrocíclicos como inibidores do vírus da hepatite c
BR112012002508A2 (pt)	2016-03-15	derivados de feniletinila como inibidores de vírus de hepatite c
ES2643164T3 (es)	2017-11-21	Indol 7-sustituido como inhibidores de Mcl-1
BRPI0908240A2 (pt)	2017-10-10	inibidores do vírus da hepatite c
BRPI0907733A2 (pt)	2015-07-14	Inibidores do vírus da hepatite c
BRPI0906625A2 (pt)	2015-07-14	Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
BRPI0820085A2 (pt)	2019-09-24	compostos contendo quinoxalina como inibidores de vírus da hepatite c
BRPI0911444A2 (pt)	2015-09-29	benzoimidazóis como inibidores de prolil hidroxilase
BRPI1007836A2 (pt)	2015-09-01	Inibidores do vírus c da hepatite
BRPI1008846A2 (pt)	2019-09-24	inibidores do vírus da hepatite c
BRPI1013393A2 (pt)	2016-03-29	inibidores do vírus da hepatite c
BRPI1014084A2 (pt)	2016-04-19	inibidores do vírus da hepatite c
BRPI0923497A2 (pt)	2019-09-24	derivados de piridazinona
EP2266989A4 (en)	2011-10-12	HETEROCYCLIC DERIVATIVES
BRPI0915064A2 (pt)	2015-10-27	derivados de qunoxalinadiona
BRPI0809221A2 (pt)	2019-09-24	indol carboxamidas como inibidores de ikk2
BRPI1008855A2 (pt)	2016-03-15	derivados de indol como agentes anticâncer
BRPI0913832A2 (pt)	2015-10-20	derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0914942A2 (pt)	2015-08-11	Compostos de oxindol
IL207684A0 (en)	2010-12-30	Substituted indole derivatives
BRPI0912234A2 (pt)	2015-10-06	derivados de salinosporamida como inibidores de proteassomas
PT2513105E (pt)	2014-07-31	Derivados de 2-arilimidazole como inibidores da enzima pde10a
BR112013002122A2 (pt)	2016-09-20	derivados hetero-bicíclicos como inibidores de hcv
BRPI0913234A2 (pt)	2016-01-19	derivados de tiazolilpiperidina

Legal Events

Date	Code	Title	Description
2016-02-10	B25D	Requested change of name of applicant approved	Owner name: JANSSEN R AND D IRELAND (IE)
2016-03-01	B25A	Requested transfer of rights approved	Owner name: JANSSEN SCIENCES IRELAND UC (IE)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-04-30	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-08-20	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-12-17	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-02-18	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/02/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF